Sage Journals: Discover world-class research

Abstract

Chronic respiratory diseases (CRDs) are a heterogeneous group of diseases that can affect the pediatric population and health authorities throughout the world recommend influenza vaccination because of the significant risk of influenza-related complications. However, despite this recommendation, vaccine coverage is generally unsatisfactory. The aim of this review is to analyze the impact of influenza on children at high risk of respiratory disease, and the immunogenicity, safety and efficacy of influenza vaccination in such children. The results show that there is a significant risk of influenza-related complications in preterm neonates and infants, in whom influenza vaccines are immunogenic and safe (although their efficacy has not been specifically studied). There are conflicting data concerning the effect of influenza infection on asthma morbidity in children, and whether or not influenza vaccination helps to prevent asthma exacerbations. Recent data provide no evidence that influenza is more frequent in patients with cystic fibrosis than in healthy subjects, or that it is responsible for increased lower respiratory tract morbidity. The lack of any clear correlate of protection suggests that future studies should also consider the efficacy of the different influenza vaccines and not only evaluate them in terms of immunogenicity. Furthermore, there is a need for clinical studies to assess the effectiveness of the available vaccines in patients with other rare CRDs and other chronic underlying diseases with possibly severe respiratory involvement. It is also important to determine whether children with recurrent respiratory tract infections should be included in the list of those for whom influenza vaccination is recommended. In the meantime, given the increasing evidence of the burden of influenza on the population as a whole and the benefits associated with vaccination, annual influenza vaccinations should be recommended for all children at high risk of respiratory disease and the members of their households.

Keywords

asthma chronic respiratory disease cystic fibrosis influenza influenza prevention influenza vaccination respiratory exacerbations vaccines

Introduction

Influenza is a contagious respiratory illness the clinical course of which is mainly benign and usually self-limiting. However, epidemics of influenza can occur every couple of years, and can lead to complications ranging from pneumonia to severe respiratory failure, or even death in susceptible hosts [Bhat et al. 2005; Centers for Disease Control and Prevention, 2011; Esposito and Principi, 2009]. Young children, the elderly, and people with chronic underlying conditions are especially vulnerable to the complications of influenza [Centers for Disease Control and Prevention, 2011; Esposito and Principi, 2009], and it has been reported that children with chronic respiratory diseases (CRDs), including chronic lung disease (CLD) of prematurity, asthma and cystic fibrosis (CF), are at significant risk [Blumental et al. 2011; Coffin et al. 2007; Patria et al. 2012]. For this reason, all health authorities agree in recommending influenza vaccination for patients with CRDs, although actual coverage remains generally unsatisfactory [Centers for Disease Control and Prevention, 2011; Esposito et al. 2006; Esposito and Principi, 2009; ECDC, 2012; European Union Council, 2009].

There are different types of influenza vaccines available on the market. Influenza vaccines prepared for intramuscular use and based on traditional inactivated viruses (TIVs) have been available for more than 50 years, although the first preparations based on whole viruses have been replaced by subunit and split-virus vaccines in order to reduce the incidence of adverse events [Principi and Esposito, 2012b]. Various attempts have been made to increase the immunogenicity and the efficacy of TIVs: the composition of TIVs has been modified by adding adjuvants, the amount of antigen has been increased, and other routes of administration have been tried. The addition of adjuvants was the first method used to improve TIVs, and has been the most widely studied. Some of the new adjuvants (emulsions and virosomes) have been widely evaluated and the apparently good results have led to the registration of adjuvanted influenza vaccines for use in humans, at least in some countries and in some subjects [Principi and Esposito, 2012]. In order to overcome some of the limitations of TIVs, a live attenuated influenza vaccine (LAIV) has also been registered. This contains cold-adapted, temperature-sensitive, attenuated influenza viruses, the moderate replication rate of which usually prevents them from reaching disease-inducing concentrations [Esposito et al. 2012a]. A LAIV does not have to be injected because it is administered intranasally. Unlike a TIV, which can only induce a systemic response to chemically treated viral proteins, a LAIV elicits mucosal and systemic immunity against native hemagglutinin and neuraminidase glycoproteins by generating specific nasal and serum antibodies and T-cell responses similar to those induced by natural influenza infection. Consequently, it can lead to a more substantial immune response and provide protection not only against the viruses included in the vaccine, but also against mismatched strains [Esposito et al. 2012b].

The aim of this review is to analyze the impact of influenza on children at high risk of respiratory disease as well as the immunogenicity, safety and efficacy of influenza vaccination in such children. PubMed was used to select all of the studies published in the last 15 years using the following combinations of text words: ‘influenza’ and ‘chronic respiratory disease’ or ‘chronic lung disease’ or ‘preterm’ or ‘prematurity’ or ‘asthma’ or ‘cystic fibrosis’ or ‘ciliary dyskinesia’ or ‘bronchiectasis’ or ‘airway malformation’ or ‘pulmonary fibrosis’ or ‘recurrent respiratory infection’. More than 3000 articles were found, but only papers published in English, those related to neonates, children and adolescents as well as those showing evidence-based data or presenting recommendations from scientific societies were included.

Preterm neonates and infants

Influenza is not a frequent illness in newborns because of the presence of protective antibodies acquired through the placenta or from breast milk [Wilkinson et al. 2006]. However, it may cause considerable morbidity and even mortality during the neonatal period, especially in preterm babies (i.e. with a gestational age of <37 weeks) and those with a low birth weight (i.e. <2500 g), because of a low rate of transplacental immunoglobulin G (IgG) transfer and the prematurity of the newborn’s immune system [Iwane et al. 2004; Louie et al. 2010]. The clinical manifestations of neonatal influenza are not specific (ranging from mild-to-moderate symptoms to severe sepsis-like syndrome) [Martic et al. 2011], but respiratory symptoms are predominant, with fever and apnea being among the most common.

Despite the high level of vigilance, reduced contact with infected cases, and the use of strict preventive measures in neonatal intensive care units (NICUs), there have been a number of reports of outbreaks of nosocomial influenza. In a retrospective cohort study of 54 newborns admitted to an NICU during the 1998 influenza outbreak, 6/19 infants infected with influenza A were symptomatic and a 27-week gestation twin with a birth weight of 962 g died because of virus-related hemophagocytic syndrome [Cunney et al. 2000]. Univariate analysis indicated that gestational age was associated with the development of influenza, whereas multiple logistic regression analysis found that only mechanical ventilation [odds ratio (OR 6.2; p = 0.02) and twin pregnancy (OR 7.0; p = 0.04) remained significant risk factors [Cunney et al. 2000]. Sagrera and colleagues reported 30 cases of neonates admitted to an NICU with nosocomial influenza A, and identified a low birth weight, a short gestational period, twin pregnancy and mechanical ventilation as risk factors; however, all of the cases had a favorable outcome [Sagrera et al. 2002]. In a recent study of 652 infants hospitalized because of A/H1N1/2009 influenza, 82 (13%) were admitted to an NICU [Yen et al. 2012]. A total of 27 (35%) of the hospitalized infants were preterm and most of them were affected by CLD of prematurity (92%). Moreover, seven patients died, two of whom were preterm infants admitted to an NICU upon delivery [Yen et al. 2012]. Another large-scale multicentre surveillance study estimated the rates of hospitalization due to seasonal influenza and found that 15% of the 4015 hospitalized children with laboratory-confirmed influenza had a history of prematurity [Dawood et al. 2010]. Furthermore, a surveillance report on the 2003–2004 and 2004–2005 influenza seasons in California found that 160 children were admitted to pediatric ICUs because of severe influenza; of the 14 children who had been born prematurely (9%), two died [Louie et al. 2010].

All of these data support the fact that, regardless of the presence of CLD of prematurity, preterm neonates and infants are also at high risk of influenza infection after discharge and influenza vaccination is therefore the primary means of preventing it. Unfortunately, because influenza vaccines are only licensed from the age of 6 months regardless of gestational age [Esposito et al. 2012a], immunization of all household contacts should be recommended [Centers for Disease Control and Prevention, 2011; Esposito et al. 2012a]. However, as the actual rate of adult immunization is usually low [Shah and Caprio, 2007], neonatologists and pediatricians should consider it as a priority to inform parents that this is the case. Another preventive measure for neonates and infants aged less than 6 months is maternal influenza immunization during pregnancy, however, it is not known whether this strategy is effective in the case of prematurity [Esposito et al. 2012a; Rasmussen et al. 2012].

Preterm infants aged at least 6 months have significant hypogammaglobulinemia during the first year of life, but it has been observed that two doses of influenza vaccine one month apart can induce protective concentrations of influenza-specific antibodies [D’Angio et al. 2011; Esposito et al. 2011; Sasaki et al. 2006]. Sasaki and colleagues found that antibody responses to influenza A (H1N1 and H3N2) vaccine in 45 previously unvaccinated preterm infants aged 6–11 months seemed to be comparable with those of similarly aged full-term infants [Sasaki et al. 2006]. Furthermore, their multivariate analysis showed that serum IgG levels at the time of vaccination had no positive association with antibody responses, thus indicating that prolonged hypogammaglobulinemia had no effect on vaccine responses in preterm infants aged over 6 months [Sasaki et al. 2006]. These findings have been confirmed by a recent prospective multicentre study carried out by D’Angio and colleagues who found that the antibody responses to two doses of trivalent inactivated influenza vaccine in 36 preterm infants with a gestational age of 26–27 weeks were similar to, or greater than those of 33 full-term infants [D’Angio et al. 2011]. Esposito and colleagues found that influenza A/H1N1/2009 MF59-adjuvanted vaccine evoked a significant immune response in 105 children aged 6–23 months (35 with a gestational age of less than 32 weeks, 35 with a gestational age of 32–36 weeks and 35 full-term children), and had a good safety and tolerability profile [Esposito et al. 2011].

Although these data confirm that influenza vaccination is immunogenic and safe even in preterm infants, there is an urgent need for further research in a number of areas. It is essential to establish the best means of increasing influenza vaccination coverage in their household contacts, and there is a need for efficacy (not only immunogenicity) studies comparing the different influenza vaccines in premature infants aged at least 6 months and less than 6 months.

Children with asthma

Asthma is a common childhood disease, with a mean global prevalence of about 12% [Lai et al. 2009]. Influenza viruses play a role in wheezing and asthma exacerbation, although influenza infection seems to be less closely related to asthma than infections due to other viruses such as rhinovirus or respiratory syncytial virus [Bosis et al. 2006]. However, a number of studies have shown that a large proportion of children with laboratory-confirmed influenza who are hospitalized or attended an outpatient clinic because of acute respiratory illnesses have asthma; in addition, it was found that both outpatient attendance and hospitalization are more frequent among children with asthma [Glezen et al. 2000; Miller et al. 2008; Moineddin et al. 2008; Neuzil et al. 2000], whose annual rate of influenza-attributable hospitalization is two to four times higher than that of otherwise healthy children [Neuzil et al. 2000]. Furthermore, children with asthma and influenza are also more likely to have pneumonia, require intensive care or develop respiratory failure [Dawood et al. 2011]. The pandemic A/H1N1/2009 influenza virus has been associated with severe lung injury in patients with asthma [Libster et al. 2010; Jain et al. 2009]. More than 30% of the children experiencing an asthma attack due to pandemic A/H1N1/2009 virus were diagnosed as having pneumonia, required admission to an intensive care unit, needed mechanical ventilation or died [Hasegawa et al. 2011; Torres et al. 2012].

All health authorities recommend annual influenza vaccination for patients with asthma, including children [Centers for Disease Control and Prevention, 2011; Esposito et al. 2012b], but actual coverage is very low [Esposito et al. 2006; Patria et al. 2012]. Pediatricians tend to resist influenza vaccination because of the lack of convincing evidence concerning its efficacy in preventing asthma exacerbations (and concerns that it may even induce them) and its potentially severe complications [Esposito et al. 2006; Patria et al. 2012]. In terms of efficacy, some studies have shown that the current influenza vaccination status of children with asthma is associated with a significant reduction in the use of oral steroids [Lanthier et al. 2011], a lower rate of exacerbations [Ong et al. 2009; Smiths et al. 2002], and a decrease in acute respiratory diseases [Kramarz et al. 2001]. Other studies have found no decrease in the rate of influenza-associated exacerbations in influenza-vaccinated patients with asthma, although their duration was shorter than in those who had not been vaccinated [Bueving et al. 2004; Sugaya et al. 1994]. However, the lack of evidence of any clear efficacy in some clinical trials may have been due to their uncontrolled design, the size of the population of children with asthma, and the heterogeneous enrolment of asthma cases without adjusting for asthma severity.

Some studies have evaluated the immunogenicity of influenza vaccines in relation to steroid therapy. Some years ago, it was shown that influenza vaccination is safe and effective in children with asthma regardless of concomitant prednisone administration [Fairchok et al. 1998; Park et al. 1996]. Subsequently, a large-scale study found that the immune response to influenza A antigens was similar in patients receiving no or low-dose inhaled corticosteroids and those receiving medium- or high-dose inhaled or oral corticosteroids, but the response to influenza B antigen may be reduced in patients treated with high-dose inhaled corticosteroids [Hanania et al. 2004]. More recently, it has been observed that the use of a virosomal-adjuvanted influenza vaccine in children with asthma seems to lead to high and persistent seroprotection rates (87–90% after 1 month, and 74–77% after 6 months) regardless of steroid therapy [Zuccotti et al. 2007].

In terms of safety, there is extensive evidence that inactivated influenza vaccination is safe and well tolerated in children with asthma, and that there is no increase in the frequency of asthma exacerbations as a complication of its administration [American Lung Association Asthma Clinical Research Centers, 2001; Cates et al. 2008; Nicholson et al. 1998]. It has also been found that inactivated influenza vaccines are safe in subjects with severe egg allergy [Esposito et al. 2008; Greenhawt et al. 2011; Owens and MacGinnitie, 2011; Webb et al. 2011].

Recent studies have shown that a LAIV is more efficacious than a trivalent vaccine, and does not lead to any significant increase in adverse pulmonary outcomes even in children with moderate to severe asthma [Ashkenazi et al. 2006; Gaglani et al. 2008; Tennis et al. 2011]. In the European Union, a LAIV is approved for use in children with mild-to-moderate asthma, and further studies are needed to confirm its safety in severe asthma.

Another future action that needs to be taken is to increase influenza vaccination coverage, at least among children with moderate or severe asthma and frequent asthma exacerbations, and to evaluate the efficacy, immunogenicity and safety of adjuvanted influenza vaccines, which seem to be more effective than traditional inactivated vaccines and may reduce influenza-related complications in very young patients with asthma.

Children with cystic fibrosis

It is known that bacterial infections play a critical role in the development of significant lung damage [Dasenbrook et al. 2010; Waters et al. 2011], whereas the role of respiratory viruses in the pulmonary exacerbations of CF is still uncertain, as is the relationship between viral infections and the progression of lung damage. Previous studies may have underestimated the prevalence of viral infections because it is only recently that molecular-based techniques have improved the detection of respiratory viruses. In this regard, a recent cross-sectional study has found that children with CF are frequently positive for at least one respiratory virus during a pulmonary exacerbation, and that viral-related exacerbations are associated with more severe disease and a poorer quality of life [Asner et al. 2012]. Respiratory viruses may also contribute to the pathogenesis of bacterial exacerbations, and it has been suggested that respiratory viral infections facilitate the acquisition and colonization of Pseudomonas aeruginosa, thus affecting host pulmonary defenses [Armstrong et al. 1998; Johansen and Hoiby, 1992].

Early studies suggested that seasonal influenza viruses play a role in worsening the lung function of patients with CF [Conway et al. 2002; Pribble et al. 1990], however, more recent studies have not found any evidence that influenza is more frequent in patients with CF than in healthy subjects, or that influenza is responsible for bacterial exacerbations or changes in colonization [Olesen et al. 2006; Ortiz et al. 2010; Punch et al. 2005; Wat et al. 2008]. Two other studies have confirmed the limited role of influenza in respiratory exacerbations in children with CF, despite the widespread presence of at least one virus during their course [Asner et al. 2012; Burns et al. 2012].

The impact of pandemic A/H1N1/2009 influenza is also unclear because its role in worsening lung function is poorly understood. Published studies found pandemic A/H1N1/2009 infection in only a small percentage of cases (2–4%), however, some studies found that patients with CF with severe lung disease and in poor clinical condition were exposed to an increased risk of complications and unfavorable outcomes during the course of the disease [France et al. 2010; Nash et al. 2011; Viviani et al. 2011]. One study found that most patients experienced mild uncomplicated disease [Colombo et al. 2011]. The main limitations of the studies of the impact of influenza on patients with CF are their small sample sizes, the absence of a healthy control group, the lack of data concerning the severity of pulmonary deterioration, and the lack of information concerning influenza vaccination status. However, given the potential risks associated with influenza infection and the advantages of influenza vaccination, all health authorities recommend influenza vaccination in patients with CF [Centers for Disease Control and Prevention, 2011; Esposito et al. 2012b]. Over the last 10 years there has been a significant increase in the level of influenza vaccination coverage among patients with CF, which is now generally high although not optimal in some geographical areas. In 2009, 91.2% of the children with CF in Italy were vaccinated against influenza versus only 8.3% in the 2000–2001 season [Esposito et al. 2006; Pandolfi et al. 2011]. Coverage in France has been relatively stable but is less than in other countries (79.9% in the 2005–2006 season) [Murris-Espin et al. 2008], whereas 91% of the children with CF in the United States were vaccinated in the 2006–2007 season [Ortiz et al. 2010].

The immunogenic effect and safety of influenza vaccines in children with CF seems to be comparable with that in healthy individuals. A recent Cochrane analysis of four relatively old studies involving a total of 179 participants with CF (mainly children) concluded that all influenza vaccinations (live intranasal, trivalent inactivated, subunit with a split virus and virosomal with a subunit product) generated a satisfactory antibody response with no significant differences between them; the total adverse event rate was quite high, but none of the adverse reactions were severe [Dharmaraj and Smyth, 2009]. In another study, a single dose of the pandemic A/H1N1/2009 MF59-adjuvanted influenza vaccine led to a high seroconversion rate in patients with CF with good lung status and in generally good nutritional condition [Alghisi et al. 2011]. The vaccine was also well tolerated and the frequency of adverse events was comparable with the published data concerning other influenza vaccines [Alghisi et al. 2011]. Interestingly, Bodewes and colleagues studied influenza A virus-specific cellular and humoral responses, and observed that annually vaccinated patients with CF developed an optimal virus- specific CD4(+) T-cell and antibody response, but may have had lower cross-reactive virus-specific CD8+ T-cell responses to other subtypes of influenza A viruses [Bodewes et al. 2012]. These findings highlight the importance of developing broadly protective vaccines that provide protection against all influenza A viruses.

Overall, although the number of studies is limited and no efficacy data are available, influenza vaccines seem to be immunogenic and safe in patients with CF, although the immune response of undernourished patients with more advanced disease is not known. Further well constructed clinical studies are needed in order to assess the effectiveness of the available influenza vaccines in relation to major clinical outcome measures, such as pulmonary function and nutritional status.

Other respiratory diseases

Other rare CRDs include primary ciliary dyskinesia, non-CF bronchiectasis, airway malformation, idiopathic pulmonary fibrosis, and the respiratory involvement observed in neurological and neuromuscular diseases, congenital heart diseases and immunodeficiency. There is a lack of specific studies evaluating the impact of influenza on respiratory exacerbations in patients with these disorders or the benefits of vaccination. However, given the increasing evidence of the burden of influenza on the population as a whole and the benefits associated with vaccination, annual influenza vaccinations should be recommended in such patients (especially those with multiple pulmonary exacerbations) and the members of their households.

Another important group consists of children with recurrent respiratory tract infections (RRTIs), defined as at least eight episodes per year in children aged under 3 years, and at least six episodes per year in children aged at least 3 years [Principi et al. 2003]. RRTIs are quite common in childhood and have a considerable impact on healthcare systems. Recent studies have shown that children with RRTIs are at high risk for influenza infection and complications, and that this increases medical consultations and costs, antibiotic use, school absences and lost working days. In a retrospective study of 250 children with nonresponsive or recurrent community-acquired pneumonia (CAP) who underwent bronchoscopy with bronchoalveolar lavage, De Schutter and colleagues found a viral infection in 30.4%, with a high prevalence of respiratory syncytial virus, and influenza and para-influenza viruses [De Schutter et al. 2011]. Another study of 80 children with recurrent lower respiratory infections who underwent bronchoscopy with bronchoalveolar lavage detected viral genomes in 62.5% [Bugin et al. 2012].

Viral RRTIs may be associated with frequent and unnecessary antibiotic prescriptions [Principi et al. 2013], and this misuse may promote the growth of drug-resistant pathogenic bacteria, which is becoming a major threat to treatment efficacy [Esposito and Principi, 2002; File, 2002]. Consequently, greater priority has recently been given to preventing RRTIs by means of influenza vaccination. Esposito and colleagues studied 127 children aged between 6 months and 9 years with a history of RRTIs who were randomized to receive intranasal virosomal influenza vaccine or a control placebo [Esposito et al. 2003], and found that the vaccinated children had fewer respiratory infections and acute febrile respiratory illnesses, fewer prescribed antibiotics and antipyretics, and missed fewer school days than the controls. Similar benefits were also observed among the patients’ household contacts. The vaccine was well accepted by the children, and the adverse events were transient and mild to moderate, with fever being the most frequent symptom [Esposito et al. 2003]. Another study randomized children aged 6–71 months with a history of RRTIs to receive two doses of a LAIV or an inactivated influenza vaccine [Ashkenazi et al. 2006], and found that LAIV reduced the number of respiratory infection-related physician visits by 8.9% [90% confidence interval (CI) 1.5–15.8%), and the number of missed days of school, kindergarten or day care by 16.2% (90% CI 10.4–21.6%). These findings confirm that any type of influenza vaccination can lead to substantial health and economic benefits by reducing the number of respiratory recurrences in children with RRTIs and, in our opinion, such patients should be included in the list of those for whom influenza vaccination should be recommended.

Conclusion

Children at high risk of respiratory disease are a heterogeneous group of the pediatric population. However, there are few studies assessing the impact of influenza on respiratory exacerbations or the efficacy of influenza vaccine in such patients, which may explain why influenza vaccination coverage remains quite low in most categories. Table 1 summarizes knowledge and gaps on influenza vaccination in children at high risk of respiratory disease. The published data show that preterm neonates and infants are at significant risk of influenza-related complications, and that influenza vaccines are immunogenic and safe in such cases; however, no specific studies of their efficacy have been carried out. There is disagreement as to whether or not influenza infection increases asthma morbidity or whether or not influenza vaccination helps in preventing asthma exacerbations in children with asthma. Further studies are needed to clarify which patient subgroups are susceptible to influenza-related complications, and to demonstrate the efficacy, immunogenicity and safety of adjuvanted influenza vaccines in such patients. Recent data provide no evidence that influenza is more frequent in patients with CF than in healthy subjects, or that it is responsible for increased lower respiratory tract morbidity. However, once again, future studies should not only consider the efficacy of the different influenza vaccines but also their immunogenicity because there is a lack of any clear correlate of protection, especially in relation to adjuvanted vaccines and LAIVs. Furthermore, there is a need for well constructed clinical studies to assess the effectiveness of the available vaccines in patients with other rare CRDs and other chronic underlying diseases with possibly severe respiratory involvement. It is also important to determine whether children with RRTIs should be included in the list of those for whom influenza vaccination is recommended. In the meantime, despite the limitations of the available studies and bearing in mind the use of influenza prevention programs in healthy subjects, further efforts are needed to increase influenza vaccination coverage among children with CRDs, and to inform their families about the importance of influenza and the benefits of preventing it.

Table 1.

Knowledge and gaps on influenza vaccination in children at high risk of respiratory disease.

Patients	Knowledge	Main gaps
Preterm neonates and infants	Regardless of the presence of chronic lung disease of prematurity, these patients have a significant risk of influenza-related complications; influenza vaccines are immunogenic and safe in such patients	To establish the best means of increasing influenza vaccination coverage in their household contacts; to perform efficacy studies comparing the different influenza vaccines in premature infants aged ≥6 and <6 months
Children and adolescents with asthma	Influenza infection increases asthma morbidity and influenza vaccination helps in preventing asthma exacerbations in children and adolescents with moderate to severe asthma	To clarify which patient subgroups are susceptible to influenza-related complications, and to demonstrate the efficacy, immunogenicity and safety of adjuvanted influenza vaccines in such patients
Pediatric patients with cystic fibrosis	No evidence that influenza is more frequent in cystic fibrosis patients than in healthy subjects, or that it is responsible for increased lower respiratory tract morbidity	To assess the effectiveness of the available influenza vaccines in relation to major clinical outcome measures such as pulmonary function and nutritional status
Pediatric patients with rare chronic respiratory disease or chronic underlying diseases with possibly severe respiratory involvement	There is a lack of specific studies evaluating the impact of influenza on respiratory exacerbations in patients with these disorders, or the benefits of vaccination	To assess the effectiveness of the available vaccines
Children with recurrent respiratory tract infections	These children are at high risk of influenza infection and complications, and influenza vaccination is associated with significant benefits	To determine whether these children should be included in the list of those for whom influenza vaccination is recommended

Footnotes

Funding

This review was supported by a grant from the Italian Ministry of Health, Bando Giovani Ricercatori 2007.

Conflict of interest statement

The authors declare that they have no conflict of interest and have received no payment for preparing this manuscript.

References

Alghisi

Palma

Montemitro

Bernardi

Pontrelli

Rossi

. (2011) Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. Thorax 66: 259–260.

American Lung Association Asthma Clinical Research Centers (2001) The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 345: 1529–1536.

Armstrong

Grimwood

Carlin

Carzino

Hull

Olinsky

. (1998) Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 26: 371–379.

Ashkenazi

Vertruyen

Aristegui

Esposito

McKeith

Klemola

. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25: 870–879.

Asner

Waters

Solomon

Yau

Richardson

Grasemann

. (2012) Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 11: 433–439.

Bhat

Wright

Broder

Murray

Greenberg

Glover

. (2005) Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 353: 2559–2567.

Blumental

Huisman

Cornet

Ferreiro

De Schutter

Reynders

. (2011) Pandemic A/H1N1v influenza 2009 in hospitalized children: a multicenter Belgian survey. BMC Infect Dis 11: 313.

Bodewes

Fraaij

Geelhoed-Mieras

van Baalen

Tiddens

van Rossum

. (2012) Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children. J Virol 85: 11995–12000.

Bosis

Esposito

Niesters

Crovari

Osterhaus

Principi

(2006) Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. J Med Virol 78: 1609–1615.

10.

Bueving

Bernsen

de Jongste

van Suijlekom-Smit

Rimmelzwaan

Osterhaus

(2004) Influenza vaccination in children with asthma: randomized double-blind placebo controlled trial. Am J Respir Crit Care Med 169: 488–493.

11.

Bugin

Lunardi

Bertuola

Snijders

Bottecchia

Perissinotto

. (2012) Pediatric chronic lower respiratory disorders: microbiological and immunological phenotype. Pediatr Pulmonol 19 September (Epub ahead of print).

12.

Burns

Emerson

Kutpers

Campbell

Gibson

McNamara

. (2012) Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings. Influenza Other Respi Viruses 6: 218–223.

13.

Cates

Jefferson

Rowe

(2008) Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 16: CD000364.

14.

Centers for Disease Control and Prevention (2011) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60: 1128–1132.

15.

Coffin

Zaoutis

Rosenquist

Heydon

Herrera

Bridges

. (2007) Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 119: 740–748.

16.

Colombo

Battezzati

Lucidi

Magazzù

Motta

Alicandro

. (2011) Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax 66: 260–261.

17.

Conway

Simmonds

Littlewoog

(2002) Acute severe deterioration in cystic fibrosis associated with influenza A virus infections. Thorax 47: 112–114.

18.

Cunney

Bialachowsli

Thornley

Smaill

Pennie

(2000) An outbreak of influenza A in a neonatal intensive care unit. Infect Control Hosp Epidemiol 21: 449–454.

19.

D’Angio

Heyne

Duara

Holmes

O’Shea

Wang

. (2011) Immunogenicity of trivalent influenza vaccine in extremely-low-birth-weight, premature versus term infants. Pediatr infect Dis J 30: 570–574.

20.

Dasenbrook

Checkley

Merlo

Konstan

Lechtzin

Boyle

(2010) Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303: 2386–2392.

21.

Dawood

Fiore

Kamimoto

Bramley

Reingold

Gershman

. (2010) Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. J Pediatr 157: 808–814.

22.

Dawood

Kamimoto

D’Mello

Reingold

Gershman

Meek

. (2011) Children with asthma hospitalized with seasonal or pandemic influenza 2003–2009. Pediatrics 128: e27–e32.

23.

De Schutter

De Wachter

Crokaert

Verhaegen

Soetens

Piérard

. (2011) Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: identification of nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis 52: 1437–1444.

24.

Dharmaraj

Smyth

(2009) Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 7: CD001753.

25.

ECDC (2012) ECDC scientific advice on seasonal influenza vaccination of children and pregnant woman. Technical report. Available at: http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=967 (accessed 26 January 2013).

26.

Esposito

Bosis

Morlacchi

Baggi

Sabatini

Principi

(2012a) Can infants be protected by means of maternal vaccination? Clin Microbiol Infect 18(Suppl. 5): 85–92.

27.

Esposito

Gasparini

Martelli

Zenga

Tremolati

. (2008) Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 26: 4664–4668.

28.

Esposito

Marchisio

Cavagna

Gironi

Bosis

Lambertini

. (2003) Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21: 3162–3168.

29.

Esposito

Marchisio

Droghetti

Lambertini

Faelli

Bosis

. (2006) Influenza vaccination coverage among children with high-risk medical conditions. Vaccine 24: 5251–5255.

30.

Esposito

Montinaro

Groppali

Tenconi

Semino

Principi

(2012b) Live attenuated intranasal influenza vaccine. Hum Vaccin Immunother 8: 76–80.

31.

Esposito

Principi

(2002) Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Drug Res Up 5: 73–87.

32.

Esposito

Principi

(2009) The rational use of influenza vaccines in healthy children and in children with underlying conditions. Curr Opin Infect Dis 22: 244–249.

33.

Esposito

Pugni

Daleno

Ronchi

Valzano

Serra

. (2011) Influenza A/H1N1 MF59-adjuvated vaccine in preterm and term children aged 6 to 23 months. Pediatrics. 127: e1161–e1168.

34.

European Union Council (2009) European Union Council Recommendation on Influenza Vaccination. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF (accessed 26 January 2013).

35.

Fairchok

Trementozzi

Carter

Regnery

Carter

(1998) Effect of prednisone on response to influenza virus vaccine in asthmatic children. Arch Pediatr Adolesc Med 152: 1191–1195.

36.

File

(2002) Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 34: S17–S26.

37.

France

Tai

Masel

Moore

McMahon

Ritchie

. (2010) The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. BMC Pulm Med 10: 8.

38.

Gaglani

Pieda

Riggs

Herschler

Fewlass

Glezen

(2008) Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 27: 444–452.

39.

Glezen

Greenberg

Atmar

Piedra

Couch

(2000) Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283: 499–505.

40.

Greenhawt

Bernstein

Blessing-Moore

Cox

Khan

. (2011) Administering influenza vaccine to egg allergic recipients: a focused practice parameter update. Ann Allergy Asthma Immunol 106: 11–16.

41.

Hanania

Sockrider

Castro

Holbrook

Tonascia

Wise

. (2004) Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J All Clin Immunol 113: 717–724.

42.

Hasegawa

Hirano

Hashimoto

Haneda

Shirabe

Ichiyama

(2011) Characteristics of atopic children with pandemic H1N1 influenza viral infection: pandemic H1N1 influenza reveals ‘occult’ asthma of childhood. Pediatr Allergy Immunol 22: e119–e123.

43.

Iwane

Edwards

Szilagyi

Walker

Griffin

Weinberg

. (2004) Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113: 1758–1764.

44.

Jain

Kamimoto

Bramley

Schmitz

Benoit

Louie

. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 361: 1935–1944.

45.

Johansen

Hoiby

(1992) Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47: 109–111.

46.

Kramarz

Destefano

Gargiulo

Chen

Lieu

Davis

. (2001) Does influenza vaccination prevent asthma exacerbations in children? J Pediatr 138: 306–310.

47.

Lai

Beasley

Crane

Foliaki

Shah

Weiland

for the the ISAAC Phase Three Study Group (2009) Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 64: 476–483.

48.

Lanthier

Huston

Moquin

Eaton

Szaba

Kummer

. (2011) Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 13: 7849–7856.

49.

Libster

Bugna

Coviello

Hijano

Dunaiewsky

Reynoso

. (2010) Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 362: 45–55.

50.

Louie

Gavali

Acosta

Samuel

Winter

Jean

. (2010) Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med 164: 1023–1031.

51.

Martic

Savic

Minic

Pasic

Nedeljkovic

Janocovic

(2011) Novel H1N1 influenza in neonates: from mild to fatal disease. J Perinatol 31: 446–448.

52.

Miller

Griffin

Edwards

Weinberg

Szilagyi

Staat

. (2008) Influenza burden for children with asthma. Pediatrics 121: 1–8.

53.

Moineddin

Nie

Domb

Leong

Upshur

(2008) Seasonality of primary care utilization for respiratory diseases in Ontario: a time-series analysis. BMC Health Serv Res 8: 160.

54.

Murris-Espin

Aubert

Bosdure

Dubus

(2008) Influenza vaccination coverage in patients with cystic fibrosis followed at 12 care centers in the Greater South Region of France for the season 2005–2006. Vaccine 26: 5612–5618.

55.

Nash

Whitmill

Barker

Rashid

Whitehouse

Honeybourne

(2011) Clinical outcome of pandemic (H1N1) 2009 influenza (swine flu) in adults with cystic fibrosis. Thorax 66: 259.

56.

Neuzil

Wright

Mitchel

Jr. Griffin

(2000) The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 137: 856–864.

57.

Nicholson

Nguyen-Van-Tam

Ahmed

Wiselka

Leese

Ayres

(1998) Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 31: 326–331.

58.

Olesen

Nielsen

Schiotz

(2006) Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol 41: 1197–1204.

59.

Ong

Forester

Fallot

(2009) Does influenza vaccination improve pediatric asthma outcomes? J Asthma 46: 477–480.

60.

Ortiz

Neuzil

Victor

Aitken

Goss

(2010) Predictors of influenza vaccination in the cystic fibrosis foundation patient registry, 2006 through 2007. Chest 138: 1448–1455.

61.

Ortiz

Neuzil

Victor

Wald

Aitken

Goss

(2010) Influenza-associated cystic fibrosis pulmonary exacerbations. Chest 137: 852–860.

62.

Owens

MacGinnitie

(2011) Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 127: 264–265.

63.

Pandolfi

Carloni

Marino

Ciofi degli Atti

Gesualdo

Romano

. (2011) Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 30: 5172–5178.

64.

Park

Frank

Sullivan

Jindal

Baxter

(1996) Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 98: 196–200.

65.

Patria

Tenconi

Esposito

(2012) Efficacy and safety of influenza vaccination in children with asthma. Expert Rev Vaccines 11: 461–468.

66.

Pribble

Black

Bosso

Turner

(1990) Clinical manifestation of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr 117: 200–204.

67.

Principi

Esposito

(2012) Adjuvanted influenza vaccines. Hum Vaccin Immunother 8: 59–66.

68.

Principi

Esposito

Cavagna

Bosis

Droghetti

Faelli

. (2003) Recurrent respiratory tract infections in pediatric age: a population-based survey of the therapeutic role of macrolides. J Chemother 15: 53–59.

69.

Principi

Marchisio

Terranova

Zampiero

Baggi

Daleno

. (2013) Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. Hum Vaccin Immunother 9. Epub ahead of print 16 January 2013.

70.

Punch

Syrmis

Rose

Harbour

Bye

Nissen

. (2005) Method for detection of respiratory viruses in the sputa of patients with cystic fibrosis. Eur J Microbiol Infect Dis 24: 54–57.

71.

Rasmussen

Jamieson

Uyeki

(2012) Effects of influenza on pregnant women and infants. Am J Obstet Gynecol 207: S3–S8.

72.

Sagrera

Ginovart

Raspall

Rabella

Sala

Sierra

. (2002) Outbreaks of influenza A virus infection in neonatal intensive care units. Pediatr infect Dis J 21: 196–200.

73.

Sasaki

Kusuhara

Saito

Hikino

Murayama

Yamashita

. (2006) Serum immunoglobulin levels do not affect antibody responses to influenza HA vaccine in preterm infants. Vaccine 24: 2208–2212.

74.

Shah

Caprio

(2007) Trivalent inactivated influenza vaccine compliance rate in neonatal intensive care units. Adv Neonatal Care 7: 295–298.

75.

Smiths

Hak

Stalman

van Essen

Hoes

Verheij

(2002) Clinical effectiveness of conventional influenza vaccination in asthmatic children. Epidemiol Infect 128: 205–211.

76.

Sugaya

Nerome

Ishida

Matsumoto

Mitamura

Nirasawa

(1994) Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 272: 1122–1126.

77.

Tennis

Toback

Andrews

McQuay

Ambrose

(2011) A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 29: 4947–4952.

78.

Torres

Iolster

Schnitzler

Farias

Bordogna

Rufach

. (2012) High mortality in patients with influenza A pH1N1 2009 admitted to a pediatric intensive care unit: A predictive model of mortality. Pediatr Crit Care Med 13: e78–e83.

79.

Viviani

Assael

Kerem

for the The ECFS (A) H1N1 Study Group (2011) Impact of the A (H1N1) pandemic influenza (season 2009–2010) on patients with cystic fibrosis. J Cyst Fibros 10: 370–376.

80.

Wat

Gelder

Hibbits

Cafferty

Bowler

Pierrepoint

. (2008) The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 7: 320–328.

81.

Waters

Yau

Prasad

Atenafu

Crandall

. (2011) Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 183: 635–640.

82.

Webb

Petersen

Boden

LaBelle

Bird

Howell

. (2011) Single-dose influenza vaccination of patients with egg allergy in a multicentre study. J Allergy Clin Immunol 128: 218–219.

83.

Wilkinson

Buttery

Andersen

(2006) influenza in the neonatal intensive care unit. J Perinatol 26: 772–776.

84.

Yen

Louie

Schechter

(2012) Infants hospitalized in intensive care units with 2009 H1N1 influenza infection, California, 2009–2010. Pediatr Infect Dis J 31: e52–e55.

85.

Zuccotti

Amendola

Viganò

Pariani

Zappa

Pogliani

. (2007) Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 25: 6692–6698.

Influenza vaccination in children at high risk of respiratory disease

Abstract

Keywords

Introduction

Preterm neonates and infants

Children with asthma

Children with cystic fibrosis

Other respiratory diseases

Conclusion

Footnotes

Funding

Conflict of interest statement

References